2-Aminoimidazoles Inhibit Mycobacterium abscessus Biofilms in a Zinc-Dependent Manner

Int J Mol Sci. 2022 Mar 9;23(6):2950. doi: 10.3390/ijms23062950.

Abstract

Biofilm growth is thought to be a significant obstacle to the successful treatment of Mycobacterium abscessus infections. A search for agents capable of inhibiting M. abscessus biofilms led to our interest in 2-aminoimidazoles and related scaffolds, which have proven to display antibiofilm properties against a number of Gram-negative and Gram-positive bacteria, including Mycobacterium tuberculosis and Mycobacterium smegmatis. The screening of a library of 30 compounds led to the identification of a compound, AB-2-29, which inhibits the formation of M. abscessus biofilms with an IC50 (the concentration required to inhibit 50% of biofilm formation) in the range of 12.5 to 25 μM. Interestingly, AB-2-29 appears to chelate zinc, and its antibiofilm activity is potentiated by the addition of zinc to the culture medium. Preliminary mechanistic studies indicate that AB-2-29 acts through a distinct mechanism from those reported to date for 2-aminoimidazole compounds.

Keywords: 2-aminoimidazoles; Mycobacterium abscessus; biofilm; nontuberculous mycobacteria; zinc.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Biofilms
  • Humans
  • Imidazoles / pharmacology
  • Microbial Sensitivity Tests
  • Mycobacterium Infections, Nontuberculous*
  • Mycobacterium abscessus*
  • Zinc / pharmacology

Substances

  • Anti-Bacterial Agents
  • Imidazoles
  • 2-aminoimidazole
  • Zinc